• KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017; 7:159.

    • Search Google Scholar
    • Export Citation
  • Ketteler M, et al.: Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters. Kidney Int. 2017; 92:2636.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Sprague SM, et al.: Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Am J Nephrol. 2016; 44:316325.

    • Crossref
    • Search Google Scholar
    • Export Citation

Mineral and Bone Disorders in CKD – New KDIGO Update

Restricted access

What’s the latest evidence affecting clinical management of mineral and bone disorder in chronic kidney disease? Updated recommendations by the Kidney Disease: Improving Global Outcomes (KDIGO) Global Network are now available.

The 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) guideline update has implications for diagnosis, evaluation, prevention, and treatment of secondary CKD-MBD in children and adults. The full guideline has been published as a supplement to Kidney International; an Executive Summary appears in the July issue of Kidney International.

Updating the previous guideline published in 2009, the revision reflects new research related to management

Save